Please assess the completion status of the following clinical trial:

Trial Title: Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Ovarian germ cell tumors :~  1. 20 benign ( mature cystic teratoma ).~ 2. 22 malignant ones ( 5 dysgerminoma , 8 immature teratoma and 9 yolk sac tumor).~ 3. 20 Normal ovaries .~Exclusion Criteria:~1. Epithelial ovarian tumors~2. sex cord -stromal ovarian tumors.~3. metastatic ovarian lesions.

- Gender: FEMALE
- Minimum Age: 6 Months
- Maximum Age: 1 Year
- Healthy Volunteers: f

Study Arms:
- Malignant ovarian germ cell tumors ( MOGCTs). (Type: None): 22 cases of malignant ovarian germ cell tumors ; include Dysgerminoma , yolk sac tumor and immature teratomas will be treated by anti P16 antibody and Ki67 antibody.
- Mature cystic teratomas. (Type: None): 20 cases of mature teratomas will be treated by anti P16 antibody .
- Normally apparent ovaries. (Type: None): 20 cases of normally apparent ovaries will be treated by anti P16 antibody .

Based on this trial design, predict the completion outcome and termination type (if applicable).